How India Exports Fluorouracil to the World

Fluorouracil has a longstanding presence in the U.S. pharmaceutical market, with multiple Abbreviated New Drug Applications (ANDAs) approved by the FDA. For instance, Gensia Sicor Pharmaceuticals received approval for ANDA #040333 on February 11, 2000. The FDA's Orange Book lists numerous approved generic versions, reflecting the drug's established therapeutic use and the competitive landscape among manufacturers.

The substantial export volume from India to the U.S., with 49.4% of total exports directed there, underscores the importance of compliance with FDA regulations. Indian exporters must adhere to stringent FDA requirements, including Good Manufacturing Practices (GMP), to ensure product quality and safety. The presence of 231 active Indian exporters highlights the competitive nature of the market, necessitating continuous regulatory vigilance to maintain market access.

In the European Union, fluorouracil is subject to the European Medicines Agency's (EMA) regulatory oversight. The EMA conducts periodic safety update report single assessments (PSUSAs) for fluorouracil, leading to variations in marketing authorizations to enhance safety and efficacy. For example, a PSUSA procedure (PSUSA/00000007/202312) concluded in November 2024 resulted in updates to product information. (ema.europa.eu)

The United Kingdom, through the Medicines and Healthcare products Regulatory Agency (MHRA), aligns with EMA standards, ensuring that fluorouracil products meet rigorous safety and efficacy criteria. Compliance with EU Good Manufacturing Practice (GMP) guidelines is mandatory for manufacturers, emphasizing quality assurance throughout the production process.

Fluorouracil is included in the World Health Organization's (WHO) Model List of Essential Medicines, underscoring its critical role in cancer treatment. The 20th edition of the list, published in March 2017, lists fluorouracil for indications such as early-stage breast cancer, colon cancer, rectal cancer, metastatic colorectal cancer, and nasopharyngeal cancer. (iris.who.int) This inclusion highlights the drug's global therapeutic importance and the necessity for adherence to international pharmacopoeia standards, including those of the United States Pharmacopeia (USP), British Pharmacopoeia (BP), European Pharmacopoeia (EP), and Indian Pharmacopoeia (IP).

In India, fluorouracil is classified under Schedule H of the Drugs and Cosmetics Act, indicating that it is a prescription-only medication. The Central Drugs Standard Control Organization (CDSCO) oversees its regulation, ensuring compliance with national standards. While fluorouracil is not listed under the Drug Price Control Order (DPCO) by the National Pharmaceutical Pricing Authority (NPPA), manufacturers must obtain a No Objection Certificate (NOC) from the Directorate General of Foreign Trade (DGFT) for export purposes, ensuring adherence to export regulations.

Fluorouracil's primary patents have expired, leading to a competitive generic market. The absence of active patents facilitates the production and export of generic versions by multiple manufacturers, contributing to the drug's widespread availability and affordability.

In November 2024, the EMA's PSUSA procedure (PSUSA/00000007/202312) for fluorouracil resulted in variations to marketing authorizations, reflecting ongoing efforts to enhance drug safety and efficacy. (ema.europa.eu)

In October 2024, the EMA reported a shortage of fluorouracil injections due to manufacturing capacity issues at a major production site in India. The shortage was anticipated to last until 2025, prompting regulatory bodies to monitor the situation closely and engage with alternative manufacturers to mitigate the impact. (ema.europa.eu)

These developments underscore the dynamic nature of the pharmaceutical industry and the importance of regulatory compliance and proactive supply chain management for Indian exporters of fluorouracil.

Fluorouracil, a critical chemotherapeutic agent, is predominantly manufactured in India. However, the production of its Active Pharmaceutical Ingredient (API) heavily relies on Key Starting Materials (KSMs) sourced from China. This dependency is significant, as China controls approximately 70–80% of the global KSM supply and 60–70% of the global intermediate supply, making it a global leader in this sector. Such reliance exposes the supply chain to vulnerabilities stemming from geopolitical tensions, trade disputes, and regulatory changes in China.

Recent disruptions have underscored these risks. In August 2024, the European Medicines Agency (EMA) reported a shortage of fluorouracil injections due to manufacturing capacity issues at a key Indian facility. These issues were partly attributed to delays in receiving essential raw materials from China, highlighting the fragility of the supply chain. (ema.europa.eu) Such incidents emphasize the need for diversified sourcing strategies to mitigate potential supply disruptions.

The export market for fluorouracil from India is notably concentrated. The top five exporters—INTAS PHARMACEUTICALS LIMITED, ALEMBIC PHARMACEUTICALS LIMITED, NAPROD LIFE SCIENCES PRIVATE LIMITED, GLAND PHARMA LIMITED, and NV REMEDIES PRIVATE LIMITED—collectively account for 78.3% of total exports. INTAS PHARMACEUTICALS LIMITED alone holds a 26.4% share, indicating a significant reliance on a limited number of suppliers. This concentration poses a risk, as any operational or compliance issues within these key companies could lead to substantial supply disruptions.

To address such vulnerabilities, the Indian government has implemented the Production Linked Incentive (PLI) scheme aimed at boosting domestic production of critical APIs and reducing dependence on imports. In November 2024, two new manufacturing units were inaugurated under this scheme to produce essential molecules like Penicillin G and 6-APA, which are vital for antibiotic production. While these initiatives are steps toward enhancing self-reliance, their impact on fluorouracil's supply chain remains to be fully realized.

Global shipping routes, including the Red Sea and the Strait of Hormuz, are critical for the transportation of pharmaceutical ingredients. Any geopolitical tensions or conflicts in these regions can disrupt supply chains, leading to delays and increased costs. Additionally, escalating trade tensions between the U.S. and China have the potential to impact the availability and pricing of KSMs essential for fluorouracil production.

Regulatory agencies have also highlighted supply concerns. In February 2026, the U.S. Food and Drug Administration (FDA) issued safety labeling changes for fluorouracil injection products, emphasizing the risks associated with dihydropyrimidine dehydrogenase (DPD) deficiency. While this update focuses on patient safety, it also underscores the importance of consistent supply to meet regulatory standards and patient needs.

• Diversify Supplier Base: Engage with multiple suppliers across different regions to reduce dependency on a limited number of exporters and mitigate risks associated with supplier-specific disruptions.

• Enhance Domestic Production: Invest in local manufacturing capabilities for both APIs and KSMs to decrease reliance on imports, particularly from geopolitically sensitive regions.

• Monitor Geopolitical Developments: Establish a dedicated team to track international events that could impact supply chains, enabling proactive adjustments to sourcing and logistics strategies.

• Strengthen Regulatory Compliance: Ensure all suppliers adhere to international quality standards and regulatory requirements to prevent disruptions due to compliance issues.

• Develop Contingency Plans: Create comprehensive risk management plans that include alternative sourcing strategies, inventory buffers, and flexible logistics arrangements to respond swiftly to potential disruptions.

RISK_LEVEL: HIGH